Secondary Logo

Seizing the Future

What's Next for the Journal of Cardiovascular Pharmacology?

Booz, George W., PhD, FAHA

Journal of Cardiovascular Pharmacology: January 2019 - Volume 73 - Issue 1 - p 1–2
doi: 10.1097/FJC.0000000000000630

Department of Pharmacology and Toxicology, University of Mississippi Medical Center, Jackson, MS.

Reprints: George W. Booz, PhD, FAHA, Department of Pharmacology and Toxicology, School of Medicine, University of Mississippi Medical Center, 2500 North State St, Jackson, MS 39216-4505 (e-mail:

The author reports no conflicts of interest.

Received October 17, 2018

Accepted October 17, 2018

The first issue of 2019 and the start of my term as Editor-in-Chief is an appropriate time to convey some of the exciting plans in store for the Journal of Cardiovascular Pharmacology. One notable change to the editorial team is that Richard Roman will join Steve Feinmark and Susan Steinberg as an Associate Editor. Rich is a recent recipient of the prestigious Excellence Award for Hypertension Research from the American Heart Association. He is a highly regarded investigator of the role of cytochrome P450 metabolites of arachidonic acid, in particular 20-HETE, in the development of hypertension-induced renal and cerebrovascular disease. Rich will help us expand the Journal's coverage of hypertension, eicosanoids, cerebrovascular disease, and the impact of genetics, immunology, and metabolism on cardiovascular disease from a pharmacological perspective. Aging, redox signaling, and sex differences are areas of consideration for further development by the Journal as well.

The Journal has an esteemed international Editorial Board and many of its members will be asked to stay on for an additional term. The success of the Journal very much depends on their hard work and dedication, and we are grateful for the opportunity to work with them. New members will be recruited from promising young researchers from around the world. We are very cognizant that the Editorial Board is not simply a pool of reviewers. Rather, the board is very much a community of basic scientists and research clinicians from both academia and industry with a shared interest in cardiovascular pharmacology and research, and I hope to engage the members of the board in the Journal's direction and operations. To that end, the Associate Editors and I will be soliciting their input into how the Journal can be more responsive to their research interests and needs.

JCVP needs to do a better job communicating the contents of the Journal to the scientific community, which nowadays means a judicious use of established social media outlets, such as Twitter and Facebook. Steve Feinmark is spearheading these efforts and 1 or 2 young scientists will help him promote our top journal articles, as well as events and conferences of interest to the Journal's readership. The board can certainly help in these efforts as well.

We will continue to provide timely review series to increase our audience and scientific impact of JCVP. Two series involving contributions from prominent experts are in the works. Dr. Antonio Abbate is putting together a series on the NLRP3 inflammasome, covering recent developments, as well as “hot” and “unsolved” issues. Dr. Robert Lukowski is organizing a review series dealing with various aspects of cGMP signaling in the heart. Promoting these series and previous collections through social media and the JCVP web site will be a priority.

Our Drugs in the Pipeline series has received a favorable response in the past and will continue to be a regular feature. One of the Associate Editors will assume responsibility for selecting relevant and timely topics, and soliciting contributions. To further extend the scientific importance of the Journal, we will begin publishing brief reviews on hot topics in cardiovascular pharmacology of interest to both clinician and researcher. We encourage all board members to submit a brief review in their interest area, as well as their own original research manuscripts. Submissions from the readership, of course, will be welcomed as well.

We will seek ways of enhancing the submission process for the Journal. The design of the Journal's web site will continue to evolve to include current editor picks, more issue highlights with colorful graphics, commentaries, and latest tweets. Ways of sending the current electronic table of contents to members of professional societies with similar interests as the Journal's will be sought. Efforts will be made to decrease the time from submission to first decision, as well as the time from acceptance to online publication. In summary, our goal is to enhance all interactions with JCVP so that they are more expeditious, informative, seamless, and enjoyable. Other changes will come about as we reach out and engage our board members, reviewers, and readership.

Copyright © 2019 Wolters Kluwer Health, Inc. All rights reserved.